CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for La Jolla Pharmaceutical Company is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

La Jolla Pharmaceutical Company
201 Jones Road, Suite 400
Phone: (617) 715-3600p:617 715-3600 WALTHAM, MA  02451  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 8/22/2022.
This company ceased filing statements with the SEC on 9/1/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
La Jolla Pharmaceutical Company is primarily engaged in the commercialization of therapies for patients suffering from life-threatening diseases. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Kevin C.Tang 54 8/1/2014 8/1/2014
President, Chief Executive Officer, Director Larry G.Edwards 50 10/29/2020 7/28/2020
Chief Financial Officer Michael S.Hearne 58 6/1/2020 6/1/2020
5 additional Officers and Directors records available in full report.

Business Names
Business Name
La Jolla Pharma, LLC
La Jolla Pharmaceutical Australia Pty Ltd
La Jolla Pharmaceutical Holdings, LLC
7 additional Business Names available in full report.

General Information
Number of Employees: 61 (As of 12/31/2021)
Outstanding Shares: 24,936,883 (As of 8/1/2022)
Shareholders: 4
Stock Exchange: NASD
Federal Tax Id: 330361285
Fax Number: (302) 655-5049
Email Address: investor.relations@ljpc.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, April 1, 2024